The anti-tumor effect following cytofectin-mediated delivery of anti-RhoA and anti-RhoC siRNAs was evaluated in a breast cancer mouse model, developed by employing 4 × 106 of MDA-MB-231 cells (human breast carcinoma cells) into female athymic nude mice of 6 weeks of age. Here, RHOC is linked to neoplasm.